<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="87985"><DrugName>doxorubicin (EGFR-targeted bacteria-derived nanocells, glioblastoma), EnGeneIC</DrugName><DrugSynonyms><Name><Value>doxorubicin (EGFR-targeted bacteria-derived nanocells, glioblastoma), EnGeneIC</Value></Name><Name><Value>VEDVDox</Value></Name><Name><Value>EDV-dox</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>(EGFR)-EDV-dox</Value></Name><Name><Value>23214-92-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="30135">EnGeneIC Ltd</CompanyOriginator><CompaniesPrimary><Company id="30135">EnGeneIC Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="30135" type="Company"><TargetEntity id="5035565563" type="organizationId">Engeneic Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"/><TargetEntity id="D005909" type="MeSH"/><TargetEntity id="360" type="ORPHANET"/><TargetEntity id="-1357419475" type="omicsDisease"/><TargetEntity id="678" type="siCondition"/></SourceEntity><SourceEntity id="2726" type="ciIndication"><TargetEntity id="10029260" type="MEDDRA"/><TargetEntity id="D009447" type="MeSH"/><TargetEntity id="635" type="ORPHANET"/><TargetEntity id="-2062438551" type="omicsDisease"/><TargetEntity id="712" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity><SourceEntity id="138" type="Action"><TargetEntity id="1065" type="Mechanism">DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="416" type="Mechanism">DNA-Directed DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="3618" type="Mechanism">Nucleic Acid Polymerase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00682" type="ciTarget"><TargetEntity id="201985772919563" type="siTarget">Epidermal growth factor receptor</TargetEntity><TargetEntity id="233" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01878" type="ciTarget"><TargetEntity id="99171" type="siTarget">DNA Topoisomerase II (fungal)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2454">Glioblastoma</Indication><Indication id="2726">Neuroblastoma</Indication></IndicationsPrimary><ActionsPrimary><Action id="138">DNA polymerase inhibitor</Action><Action id="142">Topoisomerase II inhibitor</Action><Action id="3605">Epidermal growth factor receptor modulator</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1668">Nanoparticle formulation</Technology><Technology id="603">Systemic formulation unspecified</Technology><Technology id="1">Antibody</Technology></Technologies><LastModificationDate>2019-06-28T05:54:46.000Z</LastModificationDate><ChangeDateLast>2018-03-02T00:00:00.000Z</ChangeDateLast><AddedDate>2013-10-18T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30135" linkType="Company"&gt;EnGeneIC&lt;/ulink&gt; is developing VEDVDox (EDV-dox; (EGFR)-EDV-dox), bacteria-derived anucleate nanocells, developed using the company's proprietary EDV nanocell platform, containing doxorubicin and coated with anti-EGFR bispecific antibodies to target them toward tumor cells, for the potential treatment of glioblastoma and neuroblastoma [&lt;ulink linkID="1442570" linkType="Reference"&gt;1442570&lt;/ulink&gt;], [&lt;ulink linkID="1695526" linkType="Reference"&gt;1695526&lt;/ulink&gt;], [&lt;ulink linkID="2009456" linkType="Reference"&gt;2009456&lt;/ulink&gt;].  In February 2017, a phase I trial began in the US for recurrent glioblastoma multiforme [&lt;ulink linkID="1902522" linkType="Reference"&gt;1902522&lt;/ulink&gt;].  In March 2018, preclinical data in neuroblastoma were published [&lt;ulink linkID="2009456" linkType="Reference"&gt;2009456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was previously developing VEDVDox in Australia. In February 2013, a phase I/II trial in glioblastoma was initiated in Australia. By May 2016, the trial had been terminated [&lt;ulink linkID="1442570" linkType="Reference"&gt;1442570&lt;/ulink&gt;], [&lt;ulink linkID="1695526" linkType="Reference"&gt;1695526&lt;/ulink&gt;]. However, no further development has since been reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In February 2017, the US FDA granted Orphan designation to EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse mAb for the treatment of glioblastoma multiforme [&lt;ulink linkID="1902479" linkType="Reference"&gt;1902479&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2018, EnGeneIC was planning to investigate the activity of the drug in pediatric neuroblastoma patients [&lt;ulink linkID="2009456" linkType="Reference"&gt;2009456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, a phase I trial was underway in doxorubicin-naive patients (Tailored-EDV trial) [&lt;ulink linkID="1759526" linkType="Reference"&gt;1759526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2016, a phase I trial had been completed in Australia [&lt;ulink linkID="1759526" linkType="Reference"&gt;1759526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, the company was planning to file an IND to the FDA  to initiate a phase I/II trial in early 2015 [&lt;ulink linkID="1584504" linkType="Reference"&gt;1584504&lt;/ulink&gt;]. In January 2015, the phase I/IIa trial was expected to start in mid 2015 [&lt;ulink linkID="1624290" linkType="Reference"&gt;1624290&lt;/ulink&gt;]. In September 2015, the US FDA accepted the company's IND, and a phase  I trial in glioma patients was expected to begin enrolling  before the end of 2015 [&lt;ulink linkID="1695526" linkType="Reference"&gt;1695526&lt;/ulink&gt;]. In May 2016, the company planned to initiate phase I trials in the US in 2016 [&lt;ulink linkID="1759526" linkType="Reference"&gt;1759526&lt;/ulink&gt;]. In February 2017, an open label, phase I trial (&lt;ulink linkID="260472" linkType="Protocol"&gt;NCT02766699&lt;/ulink&gt;; ENG7; CerebralEDV) began in patients with recurrent glioblastoma multiforme (estimated n = 20) in the US, to evaluate the safety and tolerability of the product in order to establish the optimum dose for future studies. The trial would also investigate efficacy and the body's immune response to the drug alongwith assessment of biomarkers [&lt;ulink linkID="1902522" linkType="Reference"&gt;1902522&lt;/ulink&gt;], [&lt;ulink linkID="1910404" linkType="Reference"&gt;1910404&lt;/ulink&gt;]. In March 2017, first patient was dosed in the trial and would be conducted in two-part; a dose exploration study would assess the safety of multiple doses of EGFR-EDV-dox and the second part would determine the recommended dose for phase II trials [&lt;ulink linkID="1910404" linkType="Reference"&gt;1910404&lt;/ulink&gt;]. In March 2018, clinical data were announced. Up to 8x10^9 nanocells given weekly were well tolerated, with no dose-limiting toxicities or withdrawals due to adverse effects [&lt;ulink linkID="2009456" linkType="Reference"&gt;2009456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, an open-label, exploratory, non-randomized, phase I/II trial (&lt;ulink linkID="141783" linkType="Protocol"&gt;ACTRN12613000297729&lt;/ulink&gt;; ENG2) to assess the safety and efficacy of the drug in patients (expected n = 46) with glioblastoma was initiated in Australia. By May 2016, the trial had been terminated [&lt;ulink linkID="1442570" linkType="Reference"&gt;1442570&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2018, preclinical data were published. Two independent human neuroblastoma xenograft studies showed that mice treated with the nanocells exhibited significant decrease in tumor size and increase in apoptosis after 28 days, compared to doxorubicin alone and to mice treated with non-targeted nanocells. Median overall survival was also significantly increased in treated mice compared to the controls [&lt;ulink linkID="2009456" linkType="Reference"&gt;2009456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data on the safety and efficacy of EGFR targeted, doxorubicin loaded EDV nanocells in 17 companion dogs diagnosed with stage IV brain tumors were published. In the study, each dog received at least seven weekly iv injections of the EGFR-targeted, doxorubicin-loaded EDV nanocells, with a maximum of 98 repeated doses. Data demonstrated that doxorubicin-loaded EDV nanocells showed a median overall survival of 264 days and the EDV nanocell treatment was found to be safe and well-tolerated. Furthermore, two dogs had complete responses, two had partial responses, 10 had stable disease and one showed progressive disease. Also, an objective response rate for the treatment was 23.53% [&lt;ulink linkID="1750097" linkType="Reference"&gt;1750097&lt;/ulink&gt;], [&lt;ulink linkID="1749918" linkType="Reference"&gt;1749918&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30135">EnGeneIC Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2017-02-01T00:00:00.000Z</StatusDate><Source id="1902522" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30135">EnGeneIC Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2726">Neuroblastoma</Indication><StatusDate>2018-03-01T00:00:00.000Z</StatusDate><Source id="2009456" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30135">EnGeneIC Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2454">Glioblastoma</Indication><StatusDate>2016-05-31T00:00:00.000Z</StatusDate><Source id="1442570" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30135">EnGeneIC Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2014-08-12T00:00:00.000Z</StatusDate><Source id="1584504" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30135">EnGeneIC Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1442570" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30135">EnGeneIC Ltd</OwnerCompany><Country id="US">US</Country><Indication id="2454">Glioblastoma</Indication><AwardedIndication>Treatment glioblastoma multiforme</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-14T00:00:00.000Z</MileStoneDate><Source id="1902479" type="CORPORATE"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00626"><Name>DNA polymerase</Name><SwissprotNumbers/></Target><Target id="PTGT-00682"><Name>Epidermal growth factor receptor</Name><SwissprotNumbers><Swissprot>P00533</Swissprot><Swissprot>P04412</Swissprot><Swissprot>P13387</Swissprot><Swissprot>P55245</Swissprot><Swissprot>Q01279</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01878"><Name>Topoisomerase II</Name><SwissprotNumbers><Swissprot>O16140</Swissprot><Swissprot>O24308</Swissprot><Swissprot>O61078</Swissprot><Swissprot>O93794</Swissprot><Swissprot>P06786</Swissprot><Swissprot>P08096</Swissprot><Swissprot>P12531</Swissprot><Swissprot>P15348</Swissprot><Swissprot>P27570</Swissprot><Swissprot>P30182</Swissprot><Swissprot>P30190</Swissprot><Swissprot>P34203</Swissprot><Swissprot>P41001</Swissprot><Swissprot>P87078</Swissprot><Swissprot>Q00942</Swissprot><Swissprot>Q01879</Swissprot><Swissprot>Q23670</Swissprot><Swissprot>Q5UQE6</Swissprot><Swissprot>Q9Y8G8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2915353" number="WO-2015049589" title="Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma"/><PatentFamily id="771288" number="WO-2005079854" title="Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Engenelc Molecular Delivery Pty Ltd" id="1107842"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="EnGeneIC Ltd" id="30135"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>